New mRNA treatment targets Hard-to-Treat cancers in early trial
NCT ID NCT07583654
First seen Jun 27, 2026 · Last updated Jul 15, 2026 · Updated 2 times
Summary
This early-phase study tests a new mRNA-based treatment for people with advanced solid tumors that have not responded to standard therapies. The treatment aims to control tumor growth by delivering a specific protein (IL-22BP) using a peptide carrier. The main goals are to check safety and see if the treatment can shrink or slow tumors in up to 18 participants.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANCER METASTATIC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
West China Hospital of Sichuan University
RECRUITINGChengdu, Sichuan, 610041, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- AI platform aims to unlock Real-World cancer data on a massive scale
- Can a genetic trait stop chemotherapy from working? a trial aims to fix that
- Can a custom mRNA vaccine keep ovarian cancer from coming back?
- AI could outshine standard tumor measurements to predict survival
- Personalized mRNA vaccine aims to train immune system against ovarian cancer
- New drug aims to fight skin cancer in transplant patients